Table 7.
Source of PHQ-9 estimates | Mean score (95% CI) |
Relative percentage accuracy from recontacted cases (95% CI) |
Conclusion drawn about accuracya |
Observed symptom score from recontacted cases | 8.11 (6.53-10.07) | N/A | N/A |
MAR PHQ-9 baseline and treatment adherence (GEE) | 7.47 (6.84-8.15) | −8 (−16 to 0) | Statistical equivalence |
MAR PHQ-9 baseline and treatment adherence (mixed) | 7.5 (6.89-8.16) | −8 (−19 to 6) | |
MAR GAD-7 baseline and treatment adherence (GEE) | 7.15 (6.7-7.63) | −12 (−24 to 3) | Statistical equivalence |
MAR GAD-7 baseline and treatment adherence (mixed) | 7.28 (6.81-7.78) | −10 (−23 to 4) | |
MAR treatment adherence (GEE) | 6.91 (6.6-7.25) | −15 (−19 to −11) | Statistical equivalence |
MAR treatment adherence (mixed) | 7.06 (6.71-7.43) | −13 (−26 to 3) | |
MAR PHQ-9 baseline (GEE) | 6.57 (6.07-7.12) | −19 (−25 to −12) | Statistical equivalence |
MAR PHQ-9 baseline (mixed) | 6.54 (6.05-7.07) | −19 (−30 to −7) | |
MAR comorbidity and education, and age (GEE) | 6.31 (5.99-6.65) | −22 (−26 to −18) | Significant underestimation |
MAR comorbidity and education, and age (mixed) | 6.33 (6.01-6.66) | −22 (−34 to −8) | |
MAR comorbidity (GEE) | 6.23 (5.9-6.57) | −23 (−27 to −19) | Significant underestimation |
MAR comorbidity (mixed) | 6.24 (5.93-6.58) | −23 (−35 to −9) | |
MAR GAD-7 baseline (GEE) | 6.09 (5.82-6.37) | −25 (−28 to −21) | Significant underestimation |
MAR GAD-7 baseline (mixed) | 6.12 (5.85-6.4) | −25 (−36 to −10) | |
MAR age (GEE) | 6.03 (5.97-6.08) | −26 (−26 to −25) | Significant underestimation |
MAR age (mixed) | 6.07 (6.01-6.13) | −25 (−39 to −8) | |
MAR Marital Status (GEE) | 6 (5.83-6.17) | −26 (−28 to −24) | Significant underestimation |
MAR marital Status (mixed) | 6.03 (5.87-6.2) | −26 (−38 to −10) | |
MAR education (GEE) | 5.96 (5.88-6.04) | −27 (−28 to −26) | Significant underestimation |
MAR education (mixed) | 5.99 (5.91-6.07) | −26 (−40 to −9) | |
MAR gender (GEE) | 5.94 (5.89-6) | −27 (−27 to −26) | Significant underestimation |
MAR gender (mixed) | 5.98 (5.93-6.03) | −26 (−40 to −9) |
aRelative accuracy from observed recontacted cases following a clinical follow-up.